Ultra-slim and highly intelligent: Roborock brings the Saros 10R to Australia
Roborock's slimmest model yet is designed to tackle family mess with precision and ease, marking a new era of household cleaning.
SYDNEY, May 22, 2025 /PRNewswire/ -- Roborock, a global leader in ultra-intelligent home robotics, has officially launched its latest robotic vacuum for its flagship Saros series – the Roborock Saros 10R – in Australia. Following the model's launch earlier this year at CES 2025, after much anticipation Aussie households can now experience the intelligent cleaning power of Roborock's slimmest robot vacuum yet — which is available from Roborock's Official Online Store and Amazon Australia from today.
Designed to easily glide under furniture and into tight corners, the Saros 10R is built for the realities of busy family life — effortlessly handling tangled cords, crumbs and clutter with powerful suction and intelligent design. That same performance extends to pet-friendly homes too, with the Dual Anti-Tangle System delivering a 100% hair removal rate and zero tangling[1] — making it ideal for the more than two-thirds[2] of Aussie households that own a pet.
Smarter navigation for stress-free cleaningForget bumping into furniture or getting stuck on stray toys — the Saros 10R uses Roborock's most advanced navigation system yet, StarSight™ 2.0. Powered by AI and a combination of smart sensors and cameras, it can spot and dodge up to 108 different household objects[1], from socks to charging cables.
Plus, the Saros 10R's VertiBeam™ Obstacle Avoidance helps it navigate these obstacles more effectively, using an additional vertical laser to improve its field of vision. This means fewer bumps into skirting boards, furniture, and cables, keeping your home intact while ensuring a more thorough clean, especially around edges and tight spaces.
Ultra-slim body meets big powerAt just 7.98cm tall, the Saros 10R is Roborock's slimmest robot vacuum ever – designed to glide under low-profile furniture like beds, sofas, and sideboards. Despite its compact form, it delivers serious performance:
20,000Pa HyperForce® suction[3] – tackles embedded dust and pet hair with ease.
AdaptiLift™ Chassis – automatically raises the vacuum by up to 10mm[1] to handle rugs, thresholds (up to 4cm), and uneven flooring.
Dual Anti-Tangle System – combines a DuoDivide® main brush and FlexiArm Riser side brush to capture hair and debris while minimising maintenance.
Mopping made easy with smart lift functionThe Saros 10R doesn't just vacuum – it mops too. Its dual spinning mops scrub hard floors with precision, then lift automatically when crossing carpets or transitioning between rooms. This prevents cross-contamination and keeps clean areas from being re-soiled. Perfect for busy households, pet owners, or anyone wanting a true 2-in-1 clean with zero hassle.
The ultimate all-in-one charging and cleaning hub
To complete the hands-free experience, the Saros 10R is compatible with the new Multifunctional Dock 4.0, which introduces significant upgrades to further streamline the user experience. Key features include:
80°C hot water mop washing[1] – for more hygienic cleaning
Auto mop removal – detaches mops when switching to vacuum-only mode or carpet cleaning
Fast charge (2.5 hours)[1] – gets the vacuum back to work quickly
Smart power management – only charges what's needed and supports off-peak scheduling
Together, these features reduce user input and increase cleaning efficiency, ensuring the Saros 10R is always ready to go.
Smarter app, smarter routinesWith the Roborock app's latest update, users gain more control than ever before. Roborock SmartPlan® 2.0 leverages AI and usage history to automatically adjust cleaning settings such as suction power, water volume, and even the cleaning route. The app also introduces convenient custom modes, automated mop washing after cleaning wet areas like kitchens and bathrooms, and compatibility with Apple Watch, smart widgets, and voice assistants – including Amazon Alexa, Google Home, Apple Siri Shortcuts, and Roborock's own "Hello, Rocky!" voice control.
Pricing and AvailabilityThe Roborock Saros 10R will be available in Australia from 22 May 2025 through Roborock's Official Online Store and Amazon Australia, at a RRP of $2,899 AUD.
For more information, visit: https://au.roborock.com
-ENDS-
About RoborockRoborock is a leading smart cleaning brand renowned for its intelligent cleaning solutions. With a steadfast dedication to becoming a global leader in smart appliances, Roborock enriches lives with its innovative line of robotic, cordless, wet/dry vacuum cleaners, and washer-dryers. Rooted in a user-centric approach, our R&D-driven solutions cater to diverse cleaning needs in over 15 million homes across 170+ countries. Headquartered in Beijing and with strategic subsidiaries worldwide, including the United States, Japan, Germany, and Australia, Roborock is committed to simplifying the way the world cleans. For more information, visit: https://au.roborock.com.
[1] Based on internal testing carried out by the manufacturer. Actual results may vary due to
environmental factors and software updates.
[2] RSPCA Australia knowledgebase
[3] Suction power values may vary by country or region. Please refer to information from your purchase channel for accurate details. Based on internal testing carried out by the manufacturer. Actual results may vary due to environmental factors and software updates.
View original content to download multimedia:https://www.prnewswire.com/apac/news-releases/ultra-slim-and-highly-intelligent-roborock-brings-the-saros-10r-to-australia-302461332.html
SOURCE Roborock
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
6 hours ago
- Yahoo
Nucleus Genomics Launches Nucleus Embryo, Genetic Optimization Software Alongside Partnership with Genomic Prediction
Parents pursuing IVF now have a new level of choice to empower their family planning NEW YORK, June 4, 2025 /PRNewswire/ -- With U.S. birthrates plummeting and IVF on the rise, Nucleus Genomics today launched Nucleus Embryo, the first genetic optimization software that lets parents see and understand a complete genetic profile to select an embryo. "Before there's a heartbeat, there's DNA," said Kian Sadeghi, founder and CEO of Nucleus. "One file containing DNA and genetic markers can tell you more about your baby's future than any other test a doctor could possibly run at this stage. Most clinics stop at whether an embryo will develop. For many parents, that's not enough. Patients have long asked for more transparency from clinics, and Nucleus Embryo is an important step toward complete data ownership for parents planning their families." The software enables parents to analyze and compare up to 20 embryos across over 900 hereditary conditions and 40 additional analyses beyond basic viability, spanning cancers, chronic conditions, appearance, cognitive ability, mental health, and more. To widen access to the software, Nucleus will partner with Genomic Prediction, the first company to offer genome-wide screening on embryos. The partnership sets a new standard in genetic medicine, continuing Genomic Prediction's decade-long history of giving hopeful parents the best possible chance of implanting healthy embryos. The company's analyses focus on hereditary conditions, acting as the first line of defense against chronic and rare diseases. "As an organization, we are committed to supporting patients' rights to their DNA and any information that can aid in their family-building journey," said Kelly Ketterson, CEO of Genomic Prediction. "We have a legacy of innovation aimed at providing patients with access to the best scientific resources. Our partnership with Nucleus opens access to information our patients have requested and allows us to uphold our commitment to this legacy." Nucleus' partnership with Genomic Prediction reflects a growing shift in how parents think about genetics as a tool to give children the best possible start in life. A wide-ranging study of Americans found the majority accepted the use of genetic technology to choose embryos based on health and personality traits. Four in 10 parents would use genetic optimization as another tool to understand their future child's cognitive abilities. Most women undergo three to six IVF cycles before successfully having a baby, with each cycle costing up to $25,000. Many embryos are unviable within days of being fertilized, leaving parents with few to choose from. Facing high stakes, clinicians often recommend genetic testing to optimize a couple's chances of a healthy pregnancy. But these tests typically stop at a select number of hereditary conditions and chromosome count. Now, advanced genetic analysis from Nucleus gives parents a new window into the health and well-being of their future child. Nucleus Embryo provides a comprehensive genetic profile for each embryo, encompassing hereditary genetic diseases, like cystic fibrosis and hemochromatosis, alongside genetic measures of cognitive ability, mental health, and risk for chronic diseases. Wide access to genetic insights for embryos can also help extend lifespan from the earliest stages of life. While more than half of all deaths annually in the U.S. are attributed to chronic, age-related conditions — such as Alzheimer's disease, diabetes, cancer, and heart disease — research shows embryonic selection can materially help reduce disease risk for these conditions. "We celebrate health optimization and the pursuit of longevity in every other part of life via our focus on training, supplements, and sleep," Sadeghi said. "We all know health isn't just the absence of disease. It's the ability to understand our bodies and genetic makeup to reach our full potential. Now we can apply this principle to life's inception." About Nucleus Genomics Nucleus builds software for generational health. Inspired by the loss of his cousin who died of a rare — yet preventable — genetic disease, Nucleus founder and Thiel Fellow Kian Sadeghi left an Ivy League university to build a product that could have saved her life. Our advanced DNA health test and analysis takes the guesswork out of your health, whether it's perfecting your protocols, knowing your risk for cancer, or planning for a healthy family. Follow us on social media @nucleusgenomics. About Genomic Prediction Genomic Prediction, Inc. is the frontrunner in advanced embryo screening. Our proprietary LifeView platform is state-of-the-art technology that assesses embryos for genetic health aimed at improved IVF outcomes. The LifeView Embryo Health Score Test (EHS) offers insight into the likelihood of developing conditions driven by multiple genes. It tests for significant health issues, including cardiovascular disease, diabetes mellitus, certain cancers, and mental health conditions. The EHS results are derived from the same embryo sample used in the following PGT tests: PGT-A: Identifies chromosome abnormalities in embryos. PGT-A+: Pinpoints the origin (paternal, maternal, or embryonic) of chromosome abnormalities. PGT-M: Decreases the chances of passing on monogenic (single-gene) conditions. PGT-SR: Detects chromosome abnormalities and structural imbalances, providing clarity between normal and balanced chromosomes. View original content to download multimedia: SOURCE Nucleus
Yahoo
8 hours ago
- Yahoo
The British Medical Journal Publishes Study Results on Sacituzumab Tirumotecan for Previously Treated EGFR-Mutant Advanced NSCLC
CHENGDU, China, June 6, 2025 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech", today announced that results from its registrational study (OptiTROP-Lung03) evaluating sacituzumab tirumotecan (sac-TMT) versus docetaxel in patients with previously treated advanced EGFR-mutant non-small cell lung cancer (NSCLC) have been published in The British Medical Journal (impact factor: 93.6). These data were also presented as an oral presentation in the Lung Cancer—Non–Small Cell Metastatic session (Abstract #8507) at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting. Based on the encouraging data from this study, sac-TMT was approved for marketing by the National Medical Products Administration (NMPA) for the treatment of adult patients with epidermal growth factor receptor (EGFR) mutant-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-tyrosine kinase inhibitor (TKI) therapy and platinum-based chemotherapy in March 2025. This marks the first global approval of a TROP2 ADC for a lung cancer indication. The published results are based on OptiTROP-Lung03, an open-label, randomized, multicenter registrational study evaluating the efficacy and safety profile of sac-TMT monotherapy versus docetaxel for the treatment of patients with locally advanced or metastatic EGFR-mutant NSCLC who have failed after treatment with an EGFR-TKI and platinum-based chemotherapy. A total of 137 patients with advanced EGFR-mutant NSCLC who had progressed after EGFR-TKI and platinum-based chemotherapy were randomized (2:1) to receive sac-TMT (5 mg/kg once every 2 weeks) or docetaxel (75 mg/m2 once every 3 weeks) until disease progression, intolerable toxicity or other reason for discontinuation, with a median follow-up time of 12.2 months (Data cutoff date: December 31, 2024). Sac-TMT achieved statistically significant and clinically meaningful outcomes compared to docetaxel: Confirmed objective response rate (ORR) (As assessed by blinded independent review committee (BIRC): 45% (95% CI, 35-56) vs 16% (95% CI, 7-30). Median progression-free survival (PFS) (As assessed by BIRC: 6.9 months [sac-TMT; 95% CI, 5.4-8.2] vs 2.8 months [docetaxel; 95% CI, 1.6-4.1], hazard ratio (HR)= 0.30 [range, 0.20 -0.46], one-sided p<0.0001; as assessed by investigator (INV): 7.9 months [sac-TMT; 95% CI, 6.2-9.5] vs 2.8 months [docetaxel; 95% CI, 1.5-3.8], HR=0.23 [95% CI, 0.15-0.36], one-sided p<0.0001). With 36.4% of patients in docetaxel group crossing over to receive sac-TMT, median overall survival (OS) was not reached (NR) for both groups (HR=0.49; 95% CI, 0.27-0.88; one-sided p=0.007). The median OS analysed by pre-specified rank-preserving structural failure time (RPSFT) model adjusted for crossover was 9.3 months for docetaxel and NR for sac-TMT (HR=0.36; 95% CI, 0.20-0.66). Efficacy benefit favored patients with sac-TMT over docetaxel across all pre-specified subgroups, including prior EGFR-TKI therapy, brain metastases, EGFR mutation type, etc. Grade ≥ 3 treatment-related adverse events (TRAEs) occurred in 56.0% of patients in sac-TMT group vs 71.7% in docetaxel group. The results demonstrated that sac-TMT monotherapy achieved statistically significant and clinically meaningful improvements in objective response rate (ORR), progression-free survival (PFS), and overall survival (OS) compared to docetaxel, with a manageable safety profile. Sac-TMT is being extensively studied in the NSCLC field. Covering treatment settings from later-line therapy to early-stage postoperative adjuvant therapy, including both monotherapy and combination regimens. Currently, five company-led registrational clinical studies for sac-TMT in NSCLC are underway in China. Meanwhile, Merck Sharp & Dohme（the tradename of Merck & Co., Inc., Rahway, NJ, USA）is also conducting five global Phase III clinical trials of sac-TMT for NSCLC in regions where it has exclusive rights. Professor Li Zhang, National Lead Principal Investigator, Medical Oncologist and Deputy Director of the Lung Cancer Research Centre at Sun Yat-Sen University, stated: "EGFR mutation is the most common driver alteration in NSCLC. The prevalence of EGFR mutations reaches 28.2% among NSCLC patients in China. Although third-generation EGFR-TKIs have become the standard of care for advanced EGFR-mutant NSCLC and may significantly improve PFS, acquired resistance remains inevitable. Combining EGFR-TKIs with chemotherapy can offer additional survival benefits to some patients, but this approach is limited by safety concerns and may compromise future treatment options, posing significant clinical challenges. The publication of the OptiTROP-Lung03 study in the British Medical Journal marks a major milestone—not only highlighting international recognition of this study outcomes in lung cancer, but also demonstrating the global competitiveness of sac-TMT as a novel TROP2 ADC." Dr. Michael Ge, CEO of Kelun-Biotech, commented: "We are thrilled to see the OptiTROP-Lung03 study published in a top-tier journal. Currently, EGFR-TKIs and chemotherapy remain the standard of care for patients with EGFR-mutant advanced NSCLC, but the challenge of increasing efficacy with manageable tolerability. The results from OptiTROP-Lung03 highlight significant survival benefits with manageable safety profile and suggest that sac-TMT could emerge as a new standard of care for this population. We remain committed to working with our partners to establish sac-TMT as a new standard of care for this patient population and improve outcomes for lung cancer patients worldwide." Registrational Study Led by Kelun-Biotech OptiTROP-Lung03: Sac-TMT monotherapy versus docetaxel for locally advanced or metastatic EGFR-mutant NSCLC after treatment failure with EGFR-TKI and platinum-containing chemotherapy； OptiTROP-Lung04: Sac-TMT monotherapy versus pemetrexed in combination with platinum for locally advanced or metastatic non-squamous NSCLC with EGFR mutations that have failed EGFR-TKI therapy； OptiTROP-Lung05: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for first-line treatment of PD-L1-positive locally advanced or metastatic NSCLC; OptiTROP-Lung06: Sac-TMT combined with pembrolizumab versus chemotherapy combined with pembrolizumab for the first-line treatment of PD-L1-negative locally advanced or metastatic non-squamous NSCLC; OptiTROP-Lung07: First-line treatment of locally advanced or metastatic NSCLC with EGFR mutations by sac-TMT in combination with ositinib. Registrational Study Led by MSD NSCLC not achieving a pCR after neoadjuvant therapy followed by surgery. NSCLC expressing PD-L1 >50% pre-treated NSCLC with EGFR mutations or other genomic alterations EGFR-mutated, advanced non-squ NSCLC progressed on prior EGFR-TK metastatic sg NSCLC About sac-TMT Sac-TMT, a core product of the Company, is a novel human TROP2 ADC in which the Company has proprietary intellectual property rights, targeting advanced solid tumors such as NSCLC, BC, gastric cancer (GC), gynecological tumors, among others. Sac-TMT is developed with a novel linker to conjugate the payload, a belotecan-derivative topoisomerase I inhibitor with a drug-to-antibody-ratio (DAR) of 7.4. Sac-TMT specifically recognizes TROP2 on the surface of tumor cells by recombinant anti-TROP2 humanized monoclonal antibodies, which is then endocytosed by tumor cells and releases KL610023 intracellularly. KL610023, as a topoisomerase I inhibitor, induces DNA damage to tumor cells, which in turn leads to cell-cycle arrest and apoptosis. In addition, it also releases KL610023 in the tumor microenvironment. Given that KL610023 is membrane permeable, it can enable a bystander effect, or in other words kill adjacent tumor cells. In May 2022, the Company licensed the exclusive rights to MSD (the tradename of Merck & Co., Inc., Rahway, NJ, USA) to develop, use, manufacture and commercialize sac-TMT in all territories outside of Greater China (includes Mainland China, Hong Kong, Macao, and Taiwan). To date, two indications for sac-TMT have been approved and marketed in China for the treatment of adult patients with unresectable locally advanced or metastatic TNBC who have received at least two prior systemic therapies (at least one of them for advanced or metastatic setting) based on the OptiTROP-Breast01 study and EGFR mutation-positive locally advanced or metastatic non-squamous NSCLC following progression on EGFR-TKI therapy and platinum-based chemotherapy based on the OptiTROP-Lung03 study. Sac-TMT became the first domestic ADC with global intellectual property rights to be fully approved for marketing. It is also the world's first TROP2 ADC to be approved for marketing in a lung cancer indication. In addition, two new indication applications for sac-TMT for the treatment of adult patients with EGFR-mutant locally advanced or metastatic NSCLC who progressed after treatment with EGFR-TKI therapy and with unresectable locally advanced, metastatic hormone receptor-positive (HR+) and human epidermal growth factor receptor 2-negative (HER2-) BC who have received prior endocrine therapy and other systemic treatments in the advanced or metastatic setting were accepted by the National Medical Products Administration (NMPA), and were reviewed via the priority review and approval process. As of today, the Company has initiated 8 registrational clinical studies in China. MSD has initiated 14 ongoing Phase 3 global clinical studies of sac-TMT as a monotherapy or with pembrolizumab or other agents for several types of cancer. These studies are sponsored and led by MSD. About Kelun-Biotech Kelun-Biotech（ a holding subsidiary of Kelun Pharmaceutical ( which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. The company focuses on major disease areas such as solid tumors, autoimmune, inflammatory, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. The Company is committed to becoming a leading global enterprise in the field of innovative drugs. At present, the Company has more than 30 ongoing key innovative drug projects, of which 3 projects have been approved for marketing, 1 project is in the NDA stage, and more than 10 projects are in the clinical stage. The company has established one of the world's leading proprietary ADC platforms, OptiDC™, and has 1 ADC project approved for marketing, 1 ADC project in NDA stage, and multiple ADC and novel coupled drug products in clinical or preclinical research stage. For more information, please visit Media: klbio_pr@ View original content to download multimedia: SOURCE Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Yahoo
11 hours ago
- Yahoo
Japanese AI Unicorn Notta Enters Otter AI's Market with Innovative Smart Voice Recorder
Notta Bets Big on AI Agent-Powered Voice Recorder as Hardware-SaaS Convergence Accelerates TOKYO, June 6, 2025 /PRNewswire/ -- As OpenAI's ChatGPT dominates enterprise AI adoption and Google Gemini reshapes how businesses think about AI assistants, Japanese unicorn Notta announced its ambitious push into the U.S. hardware market with the Notta Memo AI Voice Recorder. From Tokyo to Silicon Valley: The Underdog Story Notta's journey reads like a classic tech disruption playbook, albeit with a Japanese twist. Since launching in 2020, the company has quietly built a formidable AI transcription empire, amassing over 10 million users globally and signing up 4,000 enterprise customers. The real validation? A staggering 68% of Japan's Nikkei 225 companies—the country's most elite corporations—have integrated Notta's AI solutions into their workflows. "Most observers underestimate just how competitive the Japanese enterprise market is," explains industry analyst Sarah from TechInsight Research. "If you can win over two-thirds of the Nikkei 225, you've proven enterprise-grade reliability at scale." Notta's 2022 Airgram acquisition was just the opening move—the company believes the real opportunity lies in completely reimagining how voice technology integrates into daily workflows. Security-First Approach Gives Notta Enterprise Edge Unlike many AI startups that retrofit compliance as an afterthought, Notta built enterprise security into its foundation from day one. The company holds ISO/IEC 27001 and SOC 2 Type II certifications—credentials that remain elusive for many competitors still scrambling to meet Fortune 500 requirements. More critically, Notta has secured the regulatory trifecta that unlocks major markets: GDPR compliance for European expansion, HIPAA certification for healthcare disruption, and CCPA adherence for California's privacy-conscious landscape. This compliance-first strategy positions Notta to compete for high-value enterprise contracts that security-conscious organizations won't trust to less mature platforms. Hardware Meets AI: The Five-Platform Ecosystem Play The Notta Memo distinguishes itself in the crowded voice recording market through its unique five-platform ecosystem integration—seamlessly connecting web, iOS, Android, Chrome extension, and the Memo device itself. This comprehensive approach addresses the fragmented user experience that has long plagued the industry. Unlike traditional voice recording solutions that force users to choose between SaaS flexibility and hardware reliability, Notta Memo delivers both. The device features advanced bone-conduction technology for complete phone call recording, intelligent noise reduction for crystal-clear audio capture, and one-tap synchronization with Notta. "We're not just launching another recording device," said Ryan, CEO of Notta. "We're introducing a complete AI-powered voice ecosystem that adapts to how people work and communicate in today's hybrid world. Our hardware becomes an extension of our proven AI platform that has already transformed millions of meetings worldwide." Beyond recording, Notta Memo is your AI-powered agent and centralized knowledge hub—seamlessly integrated across all your workflows. Competitive Positioning in a Dynamic Market Notta enters the US AI transcription market with an integrated approach that combines software and hardware innovation. While the market includes established players like Otter AI in the SaaS space and Plaud AI in hardware solutions, Notta differentiates itself through its comprehensive platform that leverages AI capabilities refined through years of serving millions of global users. The company acknowledges the challenges in competing against established players with loyal American user bases. However, Notta's proven track record of rapid user acquisition and revenue growth in Japan, combined with its technological differentiation, positions it as a formidable new entrant. Market Timing and Strategic Vision Notta's American expansion comes at a pivotal moment in the AI industry. As enterprises increasingly adopt AI agents for productivity enhancement and consumers demand more intelligent, seamless technology experiences, the convergence of AI SaaS and purpose-built hardware represents a natural evolution. The Notta Memo's launch signals more than just product diversification – it represents Notta's vision of AI-native hardware that thinks, learns, and adapts to user needs. This positions the company at the forefront of the next wave of AI innovation, where the distinction between SaaS and hardware dissolves into unified, intelligent experiences. About Notta Notta is the AI unicorn that's redefining how the world captures and understands conversations. Seamlessly integrating advanced SaaS with intelligent hardware, Notta turns conversations from any meeting, call, or discussion into actionable insights. This AI-powered, end-to-end solution captures and structures spoken interactions, creating a centralized knowledge hub. Media Contact: contact@ View original content to download multimedia: SOURCE Notta
